Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

This immunotherapy company is taking the body’s T cells, which naturally fight infections, and engineering them to fight cancer. It is farthest along with its therapy for aggressive non-Hodgkin ...

Arcellx, Inc. ( ($ACLX) ) has released its Q4 earnings. Here is a breakdown of the information Arcellx, Inc. presented to its investors. Arcellx, ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been co-developing the CAR-T therapy in China. Its biopharmaceutical platform, Henlius is developing biosimilars ...